Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection.
Intestinal microbiota comprises microbial communities that reside in the gastrointestinal tract and are critical to normal host physiology. Understanding the microbiota's role in host response to invading pathogens will further advance our knowledge of host-microbe interactions. Salmonella enterica serovar Typhimurium was used as a model enteric pathogen to investigate the effect of intestinal microbiota perturbation on host susceptibility to infection. Antibiotics were used to perturb the intestinal microbiota. C57BL/6 mice were treated with clinically relevant doses of streptomycin and vancomycin in drinking water for 2 days, followed by oral infection with Salmonella enterica serovar Typhimurium. Alterations in microbiota composition and numbers were evaluated by fluorescent in situ hybridization, differential plating, and Sybr green staining. Antibiotics had a dose-dependent effect on intestinal microbiota composition. The chosen antibiotic regimen did not significantly alter the total numbers of intestinal bacteria but altered the microbiota composition. Greater preinfection perturbations in the microbiota resulted in increased mouse susceptibility to Salmonella serovar Typhimurium intestinal colonization, greater postinfection alterations in the microbiota, and more severe intestinal pathology. These results suggest that antibiotic treatment alters the balance of the microbial community, which predisposes the host to Salmonella serovar Typhimurium infection, demonstrating the importance of a healthy microbiota in host response to enteric pathogens.
Sekirov
Inna
I
Department of Microbiology and Immunology, Michael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada.
Tam
Nicola M
NM
Jogova
Maria
M
Robertson
Marilyn L
ML
Li
Yuling
Y
Lupp
Claudia
C
Finlay
B Brett
BB
D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001419:Bacteria / Q000145:classification* / Q000187:drug effects / Q000254:growth & development*; D052160:Benzothiazoles; D044822:Biodiversity; D015169:Colony Count, Microbial; D003959:Diamines; D004198:Disease Susceptibility; D005260:Female; D017404:In Situ Hybridization, Fluorescence; D007422:Intestines / Q000382:microbiology / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D009930:Organic Chemicals / Q000378:metabolism; D011804:Quinolines; D012481:Salmonella Infections, Animal; D013307:Streptomycin / Q000008:administration & dosage / Q000009:adverse effects; D014640:Vancomycin / Q000008:administration & dosage / Q000009:adverse effects
D000900:Anti-Bacterial Agents; D052160:Benzothiazoles; D003959:Diamines; D009930:Organic Chemicals; D011804:Quinolines; C098022:SYBR Green I; D014640:Vancomycin; D013307:Streptomycin